Group items tagged

Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? Cederholm T, Palmblad J. Curr Opin Clin Nutr Metab Care. 2009 Dec 16. [Epub ahead of print] PMID: 20019606 PURPOSE OF REVIEW: To report recent data on the potential role of omega-3 fatty acids (n-3 FA) found in oily fish, especially docosahexaenoic acid (DHA), to prevent and treat cognitive decline and Alzheimer's disease. RECENT FINDINGS: Observational studies still provide conflicting results, in which the majority indicate beneficial effects on cognition, both when assessed as a continuous variable or as incident dementia, mainly Alzheimer's disease. Experimental studies have demonstrated potentially ameliorating effects of eicosapentaenoic acid (EPA) and DHA on amyloid fragment formation, signal transduction including upregulation of the apolipoprotein receptor SorLA, as well as on angiogenesis. The role of EPA and DHA metabolites on Alzheimer's disease pathology is under investigation. Recently, three randomized intervention studies, with duration up to 6 months have been reported. In contrast to a small study from Taiwan, no positive overall effects were reported from the Swedish OmegAD Study or from a Dutch study, although post hoc analyses indicate that selected individuals with mild forms of Alzheimer's disease or cognitive decline may respond to treatment. SUMMARY: No firm conclusions can be drawn. Based on epidemiological data, fish including oily fish could be advised as part of a balanced diet for public health purpose, although the evidence for better cognition is only fairly consistent. It is unlikely that n-3 FA will emerge as a treatment option in general for improving cognitive function in patients with Alzheimer's disease. n-3 FA, especially DHA, may turn out as an adjuvant therapy in selected cases. Further long-term intervention studies on individuals with mild cognitive reductions are awaite"

Tofu and cognitive function: food for thought. Grodstein F, Mayeux R, Stampfer MJ. J Am Coll Nutr. 2000 Apr;19(2):207-9. Review. PMID: 10763901 In addition, a plausible biologic hypothesis is generally an important part of judging epidemiologic relations. While high tofu intake may lead to lower plasma estrogen levels [12], we do not know how tofu influences estrogen levels in the brain; we also know very little about estrogen effects in men. Furthermore, data have not even consistently indicated that low endogenous estrogen levels are directly related to cognitive function in non-demented subjects [13]. The authors also posit a non-estrogen mediated hypothesis for the effects of tofu, namely that soy inhibits hippocampal tyrosine kinase and may block long-term potentiation (the likely mechanism by which humans learn and remember). Still, considerably more work must be done to substantiate this hypothesis. Finally, the single measures of outcome used in this study may have limited value, as cognitive function and brain structure change over time. Factors which predict these measures at one point may or may not be the same as those which predict decline over time; fundamentally, the public health interest is in preventing cognitive decline, as the steepness of the decline trajectory likely provides an early marker for risk of the more clinically relevant result-dementia.

"Dec. 29, 2009 - The hot-selling herbal supplement ginkgo biloba doesn't slow age-related mental decline, a six-year clinical study shows. The study has already shown that ginkgo does not prevent dementia or Alzheimer's disease in the elderly. Now study leader Steven T. DeKosky, MD, and colleagues have sifted through the data to look for some sign that ginkgo might slow mental decline in healthy, aging individuals -- or, perhaps, in those already showing the first signs of cognitive impairment. No such sign was found. "Compared with placebo, the use of Ginkgo biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment," the researchers conclude."

"The affirmation that the omega-3 DHA can benefit cognitive and eye health offers hope to previously rejected claims. And it's business as usual regarding the overall health claims process, despite ratification of the Lisbon Treaty, said a European Commission representative. At the NutraIngredients Health Claims 2010 conference in Brussels, the EC's Lars Korsholm explained the regulatory state-of-play for DHA claims. "I think it will offer some hope to previously rejected claims in the sense that these claims that are now subject for discussion are generic in the sense that if other food business operators than those who actually submitted the application can claim to fulfill the conditions of use then they are equally entitled to use the claim," explains Korsholm. The statements come in relation to an October decision whereby the European Food Safety Authority (EFSA) affirmed that the omega-3 fatty acids, DHA and ALA, can benefit eye and cognitive development in babies. Responding to the public comment period for Merck Selbstmedikation GmbH's article 14 cognitive development claim that was rejected in March, EFSA affirmed its original stance that there was no need for additional supplementation of DHA (docosahexaenoic acid) and ALA (alpha-linolenic acid) because it already existed at adequate levels in the diet. It supported their role in foetal and newborn eye and brain development but said there was an adequate supply in breast milk. "

Vitamin D and cognitive performance in adults: a systematic review. Annweiler C, Allali G, Allain P, Bridenbaugh S, Schott AM, Kressig RW, Beauchet O. Eur J Neurol. 2009 Oct;16(10):1083-9. Epub 2009 Jul 29. PMID: 19659751 DOI: 10.1111/j.1468-1331.2009.02755.x This systematic review shows that the association between serum 25OHD concentrations and cognitive performance is not yet clearly established. The inconclusive results of the reviewed studies could be due to methodology, types of the cognitive tasks used and/or the cellular mechanisms of vitamin D.

ScienceDaily (Feb. 10, 2009) - Eating a Mediterranean diet appears to be associated with less risk of mild cognitive impairment-a stage between normal aging and dementia-or of transitioning from mild cognitive impairment into Alzheimer's disease, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals

Ginkgo has many alleged nootropic properties, and is mainly used as memory[25] and concentration enhancer, and anti-vertigo agent. However, studies differ about its efficacy. The largest and longest independent clinical trial to assess ginkgo biloba's ability to prevent memory loss has found that the supplement does not prevent or delay dementia or Alzheimer's disease.[26] Some controversy has arisen over the conclusions drawn by some studies that were allegedly funded by a firm which marketed Ginkgo.[27] In 2002, a long-anticipated paper appeared in JAMA (Journal of the American Medical Association) titled "Ginkgo for memory enhancement: a randomized controlled trial." This Williams College study, sponsored by the National Institute on Aging rather than Schwabe, examined the effects of ginkgo consumption on healthy volunteers older than 60. The conclusion, now cited in the National Institutes of Health's ginkgo fact sheet, said: "When taken following the manufacturer's instructions, ginkgo provides no measurable benefit in memory or related cognitive function to adults with healthy cognitive function." ... The impact of this seemingly damning assessment, however, was ameliorated by the almost simultaneous publication of a Schwabe-sponsored study in the less prestigious Human Psychopharmacology. This rival study, conducted at Jerry Falwell's Liberty University, was rejected by JAMA, and came to a very different-if not exactly sweeping-conclusion: There was ample evidence to support "the potential efficacy of Ginkgo biloba EGb 761 in enhancing certain neuropsychological/memory processes of cognitively intact older adults, 60 years of age and over." According to some studies, in a few cases, Ginkgo can significantly improve attention in healthy individuals.[28][29] Allegedly, the effect is almost immediate and reaches its peak in 2.5 hours after the intake.[30] [edit] In dementia A 2004 conference paper[31] summarizes how various trials indicate that Gi

Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. Wilkins CH, Birge SJ, Sheline YI, Morris JC. J Natl Med Assoc. 2009 Apr;101(4):349-54. PMID: 19397226 CONCLUSIONS: Vitamin D deficiency in older African Americans was associated with worse cognitive performance and lower BMD of the hip

A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Gleason CE, Carlsson CM, Barnet JH, Meade SA, Setchell KD, Atwood CS, Johnson SC, Ries ML, Asthana S. Age Ageing. 2009 Jan;38(1):86-93. Epub 2008 Dec 2. PMID: 19054783 doi:10.1093/ageing/afn227 Conclusions: these data suggest that administration of 100 mg/day of isoflavones was well tolerated. Plasma genistein and daidzein levels, but not equol, increased with isoflavone administration. Finally, data support the potential cognitive effects of soy isoflavones in older adults.

Association of vitamin D deficiency with cognitive impairment in older women. Cross-sectional study. Annweiler C, Schott AM, Allali G, Bridenbaugh SA, Kressig RW, Allain P, Herrmann FR, Beauchet O. Neurology. 2009 Sep 30. [Epub ahead of print] PMID: 19794127 doi:10.1212/WNL.0b013e3181beecd3 Conclusions: 25-Hydroxyvitamin D deficiency was associated with cognitive impairment in this cohort of community-dwelling older women.

Recent advances in berry supplementation and age-related cognitive decline. Willis LM, Shukitt-Hale B, Joseph JA. Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):91-4. Review. PMID: 19057194

Association between 25-hydroxyvitamin D levels and cognitive performance in middle-aged and older European men. Lee DM, Tajar A, Ulubaev A, Pendleton N, O'Neill TW, O'Connor DB, Bartfai G, Boonen S, Bouillon R, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC; EMAS study group. J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):722-9. Epub 2009 May 21. PMID: 19460797 doi:10.1136/jnnp.2008.165720 Conclusion: In this study, lower 25(OH)D levels were associated with poorer performance on the DSST. Further research is warranted to determine whether vitamin D sufficiency might have a role in preserving cognitive function in older adults.

Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment.\nLlewellyn DJ, Langa K, Lang I.\nJ Geriatr Psychiatry Neurol. 2009 Feb 4. [Epub ahead of print]\nPMID: 19073839 \ndoi:10.1177/0891988708327888\n

CHILDREN have a lot to contend with these days, not least a tendency for their pushy parents to force-feed them omega-3 oils at every opportunity. These are supposed to make children brainier, so they are being added to everything from bread, milk and pasta to baby formula and vitamin tablets. But omega-3 is just the tip of the nutritional iceberg; many nutrients have proven cognitive effects, and do so throughout a person's life, not merely when he is a child.\n\nFernando Gómez-Pinilla, a fish-loving professor of neurosurgery and physiological science at the University of California, Los Angeles, believes that appropriate changes to a person's diet can enhance his cognitive abilities, protect his brain from damage and counteract the effects of ageing

NEW YORK (Reuters Health) - New research suggests that low vitamin D levels in the body are associated with thinking or "cognitive" impairments in older men, but whether vitamin D supplements can help is not yet known. In the study, an investigation of European men, subjects with low levels of vitamin D scored worse on a standard test of cognitive ability than did their peers with normal levels, Dr. David M. Lee, from the University of Manchester, UK, and co-researchers found. Although, the authors emphasize, the difference in scores was not that great.

Katri Räikkönen, Anu-Katriina Pesonen, Kati Heinonen, Jari Lahti, Niina Komsi, Johan G. Eriksson, Jonathan R. Seckl, Anna-Liisa Järvenpää, and Timo E. Strandberg Maternal Licorice Consumption and Detrimental Cognitive and Psychiatric Outcomes in Children American Journal of Epidemiology Advance Access published on October 4, 2009. doi:10.1093/aje/kwp272 Data are compatible with adverse fetal "programming" by overexposure to glucocorticoids and caution against excessive intake of licorice-containing foodstuffs during pregnancy.

PLYMOUTH medical researchers have discovered a link between lack of the 'sunshine vitamin' and the onset of dementia.\n\nTeams from the city's Peninsula Medical School and the universities of Cambridge and Michigan have for the first time found a relationship between lower Vitamin D levels and cognitive impairment in older people.\n\nThe results of their large-scale study are to be published in the Journal of Geriatric Psychology and Neurology.

Phospholipase A(2) activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Schaeffer EL, Forlenza OV, Gattaz WF. Psychopharmacology (Berl). 2009 Jan;202(1-3):37-51. Epub 2008 Oct 14. PMID: 18853146 DOI: 10.1007/s00213-008-1351-0

Phospholipase A(2) activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Schaeffer EL, Forlenza OV, Gattaz WF. Psychopharmacology (Berl). 2009 Jan;202(1-3):37-51. Epub 2008 Oct 14. PMID: 18853146 DOI: 10.1007/s00213-008-1351-0

Nutrient and nootropic, cognitive enhancer